Dihexa 99% purity factory direct sales Low price High Quality Fast Delivery and Great Prices | Youngshe
TDS 168 Inquiries
1401708-83-5
Pharmaceutical Grade
99%
Chengdu
Chengdu Youngshe Chemical Co.,Ltd
1g/bottle, 10g/bottle,100g/bottle
2029-12-28
Peptide,Custom Peptide,KPV,MOTS-c,DSIP
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Dihexa is a synthetic peptide-based compound and angiotensin IV analog. As a research and pharmaceutical raw material, Dihexa is characterized by its defined molecular structure and peptide properties. It is primarily used for research, analytical testing, compound evaluation, and pharmaceutical development.
Certificates-
TDS
Basic Info-
Product Name:
Dihexa
Other Name:L-Isoleucinamide,N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-;N-(1-Oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide;Dihexa;N-Hexanoic-Tyr-Ile-(6)aminohexanoic amide
CAS No.:1401708-83-5
Molecular Formula:C27H44N4O5
InChIKeys:InChIKey=XEUVNVNAVKZSPT-JTJYXVOQSA-N
Molecular Weight:504.7
Exact Mass:504.66
Categories:
Characteristics-
Density:
1.111±0.06 g/cm3(Predicted)
Boiling Point:866.2±65.0 °C(Predicted)
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Peptide,Custom Peptide,KPV,MOTS-c,DSIP
-
Location:
Chengdu
-
Average lead Time:
10
-
Total Annual Revenue:
$50 million-$100 million
-
Total Employees:
11-50
-
Year of Establishment:
2015
-
-
Inquiry History168 Inquiries
Country Product Purchase Quantity Date Posted 
Canada
Dihexa lyophilized 1401708-83-5
1 Aug 23, 2026
Canada
Dihexa 1401708-83-5
1 G Mar 8, 2026 
Bulgaria
Customized peptides high purity Dihexa with fast shipping door to door CAS 1401708-83-5
10 G May 27, 2025 
United States
Dihexa
500 G Aug 19, 2026
United States
Dihexa
25 G Jan 26, 2025 
Russia
DIHEXA
50.00 G Aug 14, 2024 
Norway
Dihexa
1 G Aug 26, 2026
United States
Dihexa
1 G Aug 22, 2026
United States
Dihexa
1 G Aug 4, 2026
United States
Dihexa
1 G Jul 30, 2026
United States
Dihexa
1 G Jul 8, 2026
United States
Dihexa
10 MG Jul 6, 2026 
Australia
Dihexa
1 G Jun 30, 2026
United States
Dihexa Peptide Nootropic Neurotrophy Dihexa Powder (Pharmaceutical Grade)
1.0 G Jun 5, 2026
United States
Dihexa
1 MT May 9, 2026
United States
dihexa
1 KG May 8, 2026
Canada
Dihexa
3 G May 7, 2026
United States
Dihexa
123456 G May 4, 2026
United States
Dihexa
50 MT May 2, 2026
Canada
Dihexa
8 Apr 21, 2026 Post an enquiry for this product
